Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 2/20 | 0.38 |
| ▸ | PYGL | P06737 | 2/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16010800 | 0.85 | TYR (0.38) | SLC5A2TYR | |
| SCHEMBL14844151 | 0.85 | TYR (0.38) | SLC5A2TYR | |
| SCHEMBL14844148 | 0.85 | TYR (0.38) | SLC5A2TYR | |
| SCHEMBL8346782 | 0.80 | PYGL (0.38) | SLC5A2PYGL | |
| SCHEMBL6009962 | 0.80 | SLC5A1 (0.39) | SLC5A2PYGL | |
| SCHEMBL8520276 | 0.80 | PYGL (0.38) | SLC5A2PYGL | |
| SCHEMBL7744027 | 0.80 | PYGL (0.38) | SLC5A2PYGL | |
| SCHEMBL16010795 | 0.79 | CYP1A2 (0.41) | — | |
| SCHEMBL14843742 | 0.79 | CYP1A2 (0.41) | — | |
| SCHEMBL14843740 | 0.79 | CYP1A2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209458-B1 | SKIN TREATMENT COMPOSITIONS | OBAGI COSMECEUTICALS LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9883998-B2 | Methods for lightening skin using arbutin compositions | OMP, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160067165-A1 | METHODS FOR LIGHTENING SKIN USING ARBUTIN COMPOSITIONS | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2016-03-10 | — | — | US | disclosed |
| US-9168398-B2 | Skin treatment compositions | OMP, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20100303747-A1 | SKIN TREATMENT COMPOSITIONS | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2010-12-02 | — | — | US | disclosed |
| EP-2209458-A1 | SKIN TREATMENT COMPOSITIONS | OMP, INC. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009065008-A1 | SKIN TREATMENT COMPOSITIONS | OMP, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303747-A1 | SKIN TREATMENT COMPOSITIONS | TYR, CUTA, KLK6 | SLC5A2 1095/4885PYGL 1560/4885TYR 1/4885 |
| US-20160067165-A1 | METHODS FOR LIGHTENING SKIN USING ARBUTIN COMPOSITIONS | TYR, NAMPT, MITF | SLC5A2 977/4885PYGL 1269/4885TYR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.